Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noel Gardner

Psychiatry Salt Lake City, UT Medical Doctor

NPI 1285655746 CMS profile 285580

515 E 4500 S Ste G220, Salt Lake City, UT 84107

Open in the dashboard

General payments

$512,253

606 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Noel Gardner of Salt Lake City, UT is reported in the CMS Open Payments database as having received $512,253 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,168 24
2024 General $43,301 47
2023 General $137,101 126
2022 General $74,493 79
2021 General $68,184 93
2020 General $67,828 86
2019 General $104,178 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noel Gardner
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Noel Gardner were reported at $17,168. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Noel Gardner Psychiatry median Middle half National median
2019 $104,178 $184 $59–$605 $163
2020 $67,828 $119 $36–$372 $114
2021 $68,184 $143 $43–$576 $132
2022 $74,493 $153 $50–$590 $149
2023 $137,101 $170 $56–$651 $160
2024 $43,301 $179 $57–$673 $164
2025 $17,168 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $320,782 323 payments
  2. Allergan Inc. $156,124 204 payments
  3. Alkermes, Inc. $14,526 24 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $10,525 15 payments
  5. ACADIA Pharmaceuticals Inc $8,676 14 payments
  6. Sunovion Pharmaceuticals Inc. $744 4 payments
  7. ITI, Inc. $398 9 payments
  8. Sage Therapeutics, Inc. $151 2 payments
  9. Janssen Pharmaceuticals, Inc $132 2 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $84 4 payments
  11. Other $112 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $438,300 183 payments
  2. Travel and Lodging $52,349 222 payments
  3. Consulting Fee $13,975 4 payments
  4. Food and Beverage $7,549 191 payments
  5. Education $80 6 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $306,715 306 payments
  2. VRAYLAR Neuroscience $164,599 216 payments
  3. LYBALVI Cns $14,365 21 payments
  4. LYBALVI Cns $14,365 21 payments
  5. LYBALVI Cns $14,365 21 payments
  6. LYBALVI Cns $14,365 21 payments
  7. Trintellix Central Nervous System (CNS) $8,959 11 payments
  8. NUPLAZID $8,659 13 payments
  9. TRINTELLIX Neuroscience $1,566 4 payments
  10. LATUDA $713 3 payments
  11. Other $1,575 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record